Firma Clinical has joined the Decentralized Trials & Research Alliance (DTRA), an alliance of life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The DTRA launched in late 2020 to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations, to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants.
“As a company that has been a leader in patient centricity, Firma is pleased to be a member of DTRA and join this important initiative to advance decentralized research and make the clinical trial process more patient focused while increasing trial efficiency,” says Michael Woods, CEO, Firma Clinical. “We are pleased to be able to share ideas and insights from our Home Trial Services and Biometrics/Research Services that can help innovate clinical trials and accelerate drug and medical technology development.”
Firma’s representative for DTRA is Melissa Nezos, Vice President of Clinical Operations, and an advocate for patient-centric clinical studies. She joined Firma in mid-2020 to lead project management and clinical operations for Home Trials Services. Melissa will join other DTRA member organizations in providing expertise to identify and address gaps and needs and advance best practices through effective education and communication.
“By taking part in DTRA, Firma is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-convener, clinical innovation advisor and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”
About Firma Clinical Research
Firma Clinical Research is a quality certified CRO built on decades of clinical development leadership and expertise. Firma supports the drug development efforts of pharmaceutical and biotech companies through in-home patient visits and data management and biostatistics. Firma’s patient-centric and collaborative approach enables clients to make informed decisions that accelerate the development of safe and effective treatments. The company offers a wide array of tailored processes and services across all phases of clinical development, strategically focusing on flexible solutions, transparent communication and on-time deliverables. For more information, visit the company at www.firmaclinicalresearch.com or follow Firma Clinical Research on Twitter or LinkedIn.
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.